Media Contact
Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday:
- Andrea Greif
Senior Director, Communications
(914) 821-8958
andrea.greif@lls.org
LLS Announces New Research Program for Deadly Blood Cancer
Rye Brook, NY – Jan. 8, 2018 - The Leukemia & Lymphoma Society (LLS), the world’s largest voluntary health organization dedicated to fighting blood cancer, announced today new funding for research programs in mantle cell lymphoma (MCL) treatment through a generous donation from The Sarah Cannon Fund at The HCA Foundation. Among the 72,000 new cases per year of non-Hodgkin lymphomas (NHLs), approximately 4,...
Burlington Stores Raises More Than $32 Million For LLS
Rye Brook, NY (December 12, 2017) – For the 16th year, Burlington Stores and The Leukemia & Lymphoma Society’s (LLS) Light The Night campaign united to shine a light on the urgent need to fund blood cancer research and help patients access lifesaving treatments and cures. From September 17 through December 9, Burlington store locations across the country encouraged customers to donate $1 or more at checkout t...
LLS Achieves New Milestones in Offensive Against Deadly Blood Cancer AML
Rye Brook, NY (December 6, 2017) – The Leukemia & Lymphoma Society® (LLS) continues its assault against acute myeloid leukemia (AML), a deadly blood cancer that kills more than 10,000 Americans a year. LLS today announced its groundbreaking precision medicine Beat AML® Master Clinical Trial is seeing a rapid increase in patients enrolled as more leading cancer centers and biopharmaceutical companies...
John Quinones Appears with Blood Cancer Survivors in PSA for LLS
Rye Brook, NY, (December 7, 2017) --“If you had a chance to support research that is saving lives…What would you do?” asks John Quinones in a new public service announcement for The Leukemia & Lymphoma Society, titled “I Live.” The ABC News correspondent and host of the popular television series, What Would You Do? is featured in the compelling segments, joined by a group of children and one adult who a...
LLS Funds $46 Million in New Research to Find Cures
View multimedia release here. Rye Brook, NY (Nov. 20, 2017) - The Leukemia & Lymphoma Society® (LLS) continues to lead the charge to cancer cures through its aggressive research investment; the organization announced today it has committed an additional $46 million to fund the most innovative science at leading medical institutions around the world, including Memorial Sloan Kettering Cancer Center...
TEAM IN TRAINING LAUNCHES 30TH YEAR AT 2017 NYC MARATHON FOR CANCER CURES
View full multimedia release here. RYE BROOK, N.Y. (November 1, 2017) – The Leukemia & Lymphoma Society (LLS) is going back where it all began – 30 years ago the world’s leading non-profit dedicated to fighting blood cancers pioneered the sports endurance training for charity movement when the first Team In Training team ran the 1988 New York City Marathon. To mark this milestone, Team In Train...
Bipartisan Health Bill Would Lower Costs & Protect Patients
Rye Brook, NY (October 23, 2017) – Last week, U.S. Senators Lamar Alexander (Tennessee) and Patty Murray (Washington) released a bipartisan package of reforms intended to stabilize the nongroup insurance market, lower costs for families purchasing coverage on their own, and provide flexibility to states working to improve their health insurance options. 24 senators from both sides of the aisle have added their name...
FDA Approves Second LLS-Supported CAR T-cell Immunotherapy
Rye Brook, N.Y. (October 18, 2017) – The Leukemia & Lymphoma Society (LLS) hails today’s U.S. Food and Drug Administration (FDA) approval of a new, personalized cell therapy that supercharges the patient’s immune system to find and kill cancer cells. The therapy, axicabtagene ciloleucel (Yescarta ™), is the second of this new method of treatment, known as CAR (chimeric antigen receptor) T-cell immunothera...